{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:09:48Z","timestamp":1758125388611},"reference-count":39,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.3892\/br.2014.233","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T05:35:47Z","timestamp":1390973747000},"page":"412-418","source":"Crossref","is-referenced-by-count":4,"title":["Influence of celecoxib on the vasodilating properties of human mesenteric arteries constricted with endothelin-1"],"prefix":"10.3892","volume":"2","author":[{"given":"GRZEGORZ","family":"GRZE\u015aK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KATARZYNA","family":"SZADUJKIS-SZADURSKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GRZEGORZ","family":"MATUSIAK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BARTOSZ","family":"MALINOWSKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARTA","family":"GAJDUS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MICHA\u0141","family":"WICI\u0143SKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LESZEK","family":"SZADUJKIS-SZADURSKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,1,29]]},"reference":[{"key":"key20180107141622_b1-br-02-03-0412","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2011.12.029","article-title":"Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats","volume":"130","author":"Grze\u015bk","year":"2012","journal-title":"Thrombos Res"},{"key":"key20180107141622_b2-br-02-03-0412","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/mi.6.4.6","article-title":"COX-2 in inflammation and resolution","volume":"6","author":"Rajakariar","year":"2006","journal-title":"Mol Interv"},{"key":"key20180107141622_b3-br-02-03-0412","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-012124546-7\/50528-3","article-title":"Prostaglandin mediators","volume-title":"Handbook of Cell Signaling","author":"Smyth","year":"2003","edition":"Second Edition"},{"key":"key20180107141622_b4-br-02-03-0412","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107141622_b5-br-02-03-0412","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMp048288","article-title":"Coxibs and cardiovascular disease","volume":"351","author":"FitzGerald","year":"2004","journal-title":"N Engl J Med"},{"key":"key20180107141622_b6-br-02-03-0412","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","article-title":"Complications of the COX-2 inhibitors parecoxib and waldecoxib after cardiac surgery","volume":"352","author":"Nussmeier","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107141622_b7-br-02-03-0412","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107141622_b8-br-02-03-0412","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.amjmed.2011.02.025","article-title":"Harmful effects of NSAIDs among patients with hypertension and coronary artery disease","volume":"124","author":"Bavry","year":"2011","journal-title":"Am J Med"},{"key":"key20180107141622_b9-br-02-03-0412","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1158\/1940-6207.CAPR-09-0271","article-title":"Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial","volume":"3","author":"Bertagnolli","year":"2010","journal-title":"Cancer Prev Res"},{"key":"key20180107141622_b10-br-02-03-0412","first-page":"H326","article-title":"Corelease of nitric oxide and prostaglandins mediates flow-dependent dilation of rat gracilis muscle arterioles","volume":"267","author":"Koller","year":"1994","journal-title":"Am J Physiol"},{"key":"key20180107141622_b11-br-02-03-0412","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1161\/01.RES.0000202692.23001.e2","article-title":"Beta-adrenergic stimulation of L-type Ca2+channels in cardiac myocytes requires the distal carboxyl terminus of \u03b11Cbut not serine 1928","volume":"98","author":"Ganesan","year":"2006","journal-title":"Circ Res"},{"key":"key20180107141622_b12-br-02-03-0412","doi-asserted-by":"crossref","first-page":"C1743","DOI":"10.1152\/ajpcell.2001.281.6.C1743","article-title":"Regulation of cardiac and smooth muscle Ca2+channels (CaV1.2a,b) by protein kinases","volume":"281","author":"Keef","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"key20180107141622_b13-br-02-03-0412","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1210\/en.2007-0182","article-title":"Local actions of atrial natriuretic peptide counteract angiotensin II stimulated cardiac remodeling","volume":"148","author":"Kilic","year":"2007","journal-title":"Endocrinology"},{"key":"key20180107141622_b14-br-02-03-0412","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1161\/01.CIR.0000094403.78467.C3","article-title":"Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3\u2032,5\u2032-cyclic monophosphate-dependent protein kinase","volume":"108","author":"M\u00fcnzel","year":"2003","journal-title":"Circulation"},{"key":"key20180107141622_b15-br-02-03-0412","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/01.RES.0000087541.15600.2B","article-title":"Cyclic GMP phosphodiesterases and regulation of smooth muscle function","volume":"93","author":"Rybalkin","year":"2003","journal-title":"Circ Res"},{"key":"key20180107141622_b16-br-02-03-0412","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCRESAHA.106.144501","article-title":"cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology","volume":"100","author":"Zaccolo","year":"2007","journal-title":"Circ Res"},{"key":"key20180107141622_b17-br-02-03-0412","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"key20180107141622_b18-br-02-03-0412","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1152\/physrev.00023.2003","article-title":"Ca2+sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase","volume":"83","author":"Somlyo","year":"2003","journal-title":"Physiol Rev"},{"key":"key20180107141622_b19-br-02-03-0412","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0091270006294540","article-title":"Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766","volume":"47","author":"Oberwittler","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"key20180107141622_b20-br-02-03-0412","doi-asserted-by":"crossref","first-page":"H260","DOI":"10.1152\/ajpheart.01027.2005","article-title":"Effects of hsp90 binding inhibitors on sGC-mediated vascular relaxation","volume":"291","author":"Yetik-Anacak","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key20180107141622_b21-br-02-03-0412","doi-asserted-by":"crossref","first-page":"F1443","DOI":"10.1152\/ajprenal.00353.2006","article-title":"Novel role of AQP-1 in NO-dependent vasorelaxation","volume":"292","author":"Herrera","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"key20180107141622_b22-br-02-03-0412","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jnr.22559","article-title":"Endothelins decrease the expression of aquaporins and plasma membrane water permeability in cultured rat astrocytes","volume":"89","author":"Tanaka","year":"2011","journal-title":"J Neurosci Res"},{"key":"key20180107141622_b23-br-02-03-0412","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.transproceed.2007.02.079","article-title":"Guanylate cyclase activators influence reactivity of human mesenteric superior arteries retrieved and preserved in the same conditions as transplanted kidneys","volume":"39","author":"Slupski","year":"2007","journal-title":"Transplant Proc"},{"key":"key20180107141622_b24-br-02-03-0412","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/01.CIR.0000051361.69808.3A","article-title":"Selective COX-2 inhibition improves endothelial function in coronary artery disease","volume":"107","author":"Chenevard","year":"2003","journal-title":"Circulation"},{"key":"key20180107141622_b25-br-02-03-0412","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/01.ATV.0000253884.13901.e4","article-title":"Implications of early structural-functional changes in the endothelium for vascular disease","volume":"27","author":"Simionescu","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20180107141622_b26-br-02-03-0412","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/bjp.2008.214","article-title":"Vasorelaxation induced by prostaglandin E(2) in human pulmonary vein: role of the EP(4) receptor subtype","volume":"154","author":"Foudi","year":"2008","journal-title":"Br J Pharmacol"},{"key":"key20180107141622_b27-br-02-03-0412","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J Clin Invest"},{"key":"key20180107141622_b28-br-02-03-0412","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(04)16299-5","article-title":"Cyclooxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study","volume":"363","author":"Mamdani","year":"2004","journal-title":"Lancet"},{"key":"key20180107141622_b29-br-02-03-0412","first-page":"1143","article-title":"Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care","volume":"31","author":"Wolfe","year":"2004","journal-title":"J Rheumatol"},{"key":"key20180107141622_b30-br-02-03-0412","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.165.5.ioi50013","article-title":"Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure","volume":"165","author":"Aw","year":"2005","journal-title":"Arch Intern Med"},{"key":"key20180107141622_b31-br-02-03-0412","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00002512-200421070-00005","article-title":"Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin","volume":"21","author":"Brinker","year":"2004","journal-title":"Drugs Aging"},{"key":"key20180107141622_b32-br-02-03-0412","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A2","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"key":"key20180107141622_b33-br-02-03-0412","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cardiores.2007.02.026","article-title":"Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO\/cGMP signaling by PDE5 inhibition","volume":"75","author":"Klein","year":"2007","journal-title":"Cardiovasc Res"},{"key":"key20180107141622_b34-br-02-03-0412","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cmet.2005.08.005","article-title":"Prostacyclin protects against elevated blood pressure and cardiac fibrosis","volume":"2","author":"Francois","year":"2005","journal-title":"Cell Metab"},{"key":"key20180107141622_b35-br-02-03-0412","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00228-010-0789-2","article-title":"Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults - a nationwide registry-based study","volume":"66","author":"Gudbjornsson","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"key20180107141622_b36-br-02-03-0412","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/cvr\/cvn111","article-title":"Cyclooxygenase-dependent vasoconstricting factor(s) in remodelled rat femoral arteries","volume":"79","author":"Akiko","year":"2008","journal-title":"Cardiovasc Res"},{"key":"key20180107141622_b37-br-02-03-0412","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0300-8932(09)72067-6","article-title":"Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication","volume":"62","author":"Fl\u00f3rez","year":"2009","journal-title":"Rev Esp Cardiol"},{"key":"key20180107141622_b38-br-02-03-0412","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/01.HYP.0000084603.93510.28","article-title":"Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension","volume":"42","author":"Widlansky","year":"2003","journal-title":"Hypertension"},{"key":"key20180107141622_b39-br-02-03-0412","doi-asserted-by":"crossref","first-page":"H1882","DOI":"10.1152\/ajpheart.00092.2009","article-title":"Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits","volume":"297","author":"Foudi","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["Biomedical Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/br.2014.233\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T09:24:18Z","timestamp":1515317058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/br.2014.233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,29]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,1,29]]},"published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.3892\/br.2014.233"],"URL":"https:\/\/doi.org\/10.3892\/br.2014.233","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,29]]}}}